Update Nov Dec 2013 - (Page 34)

FDLI Activities A Look Back at Advertising and Promotion 2013: Highlights from the "Policy Updates and Enforcement Developments from FDA's Medical Product Centers" Panel By Rachael A. Vieder, Manager, Medical Devices/Drugs Portfolio; Editor Photography from FDLI's 2013 Advertising and Promotion Conference by Valter Schleder T he first session of FDLI's Annual Advertising and Promotion Conference allowed attendees to hear directly from FDA product center representatives on current regulations, enforcement actions, recent developments, perspective on comments submitted to the Agency, and insights on the future of FDA's advertising and promotion oversight. Wayne L. Pines, President, Regulatory Services and Healthcare; APCO Worldwide, led the panelists, who included Thomas W. Abrams, Director, Office of Prescription Drug Promotion, Center for Drug Evaluation and Research (CDER), Office of Medical Products and Tobacco (OMPT), 34 Update November/December 2013 FDA; Thomas J. Moskal, DVM, Dipl. ACLAM, MLIS, Veterinary Medical Officer, Post-Approval Review Team, Division of Surveillance, Center for Veterinary Medicine (CVM), Office of Foods and Veterinary Medicine, FDA; Lisa L. Stockbridge, PhD, Branch Chief, Advertising and Promotional Labeling Branch, Division of Case Management, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), FDA; and Toni Stifano, Consumer Safety Officer, Office of Compliance, Center for Devices and Radiological Health (CDRH), FDA. Thomas Abrams addressed CDER's top priorities and www.fdli.org http://www.fdli.org

Table of Contents for the Digital Edition of Update Nov Dec 2013

Update Nov Dec 2013